Cardiology

The CGTLive™ Cardiology specialty topic page contains video interviews with key opinion leaders in the field of cardiology and up-to-date clinical news coverage on the latest cardiology gene and cell therapies for heart disease. It houses information on relevant FDA actions, clinical guideline updates, and clinical trial findings related to the development of cell therapies, gene therapies, and engineered and regenerative medicines for heart conditions.

Latest News

Data Roundup: April 2025 Features Updates for Cardiomyopathy Gene Therapy, Myasthenia Gravis CAR-T, and More
Data Roundup: April 2025 Features Updates for Cardiomyopathy Gene Therapy, Myasthenia Gravis CAR-T, and More

May 2nd 2025

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Around the Helix: Cell and Gene Therapy Company Updates – April 30, 2025
Around the Helix: Cell and Gene Therapy Company Updates – April 30, 2025

April 30th 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 23, 2025
Around the Helix: Cell and Gene Therapy Company Updates – April 23, 2025

April 23rd 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 16, 2025
Around the Helix: Cell and Gene Therapy Company Updates – April 16, 2025

April 16th 2025

Verve Therapeutics’ Base Editing Therapy VERVE-102 Reduces LDL-C in Patients With HeFH and CAD
Verve Therapeutics’ Base Editing Therapy VERVE-102 Reduces LDL-C in Patients With HeFH and CAD

April 15th 2025

Video Interviews

More News

Lexeo’s Gene Therapy LX2006 Reduces Abnormal LVMI in Patients With Friedreich Ataxia Cardiomyopathy

Lexeo’s Gene Therapy LX2006 Reduces Abnormal LVMI in Patients With Friedreich Ataxia Cardiomyopathy

Noah Stansfield
April 10th 2025

The data come from patients treated across 2 studies.

Around the Helix: Cell and Gene Therapy Company Updates – April 9, 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 9, 2025

Noah Stansfield
April 9th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – April 2, 2025

Around the Helix: Cell and Gene Therapy Company Updates – April 2, 2025

Noah Stansfield
April 2nd 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Data Roundup: March 2025 Features Updates from MDA's Conference, an Alzheimer Disease Trial, and More

Data Roundup: March 2025 Features Updates from MDA's Conference, an Alzheimer Disease Trial, and More

Noah Stansfield
April 1st 2025

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

FDA Activity Recap: March 2025 Features FDA Approvals in Hemophilia, ATTR Amyloidosis, and More

Noah Stansfield
April 1st 2025

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Around the Helix: Cell and Gene Therapy Company Updates – March 26, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 26, 2025

Noah Stansfield
March 26th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Secretome Therapeutics Doses First Patient in Phase 1 Trial for Heart Failure Cell Therapy STM-01

Secretome Therapeutics Doses First Patient in Phase 1 Trial for Heart Failure Cell Therapy STM-01

Noah Stansfield
March 25th 2025

According to Secretome, the first-in-human, open-label trial is the first trial to assess an allogeneic stem cell therapy product for HFpEF.

FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy

FDA Approves Alnylam’s Vutrisiran for the Treatment of ATTR Amyloidosis With Cardiomyopathy

Noah Stansfield
March 20th 2025

The product is marketed under the name Amvuttra.

Around the Helix: Cell and Gene Therapy Company Updates – March 19, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 19, 2025

Noah Stansfield
March 19th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – March 12, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 12, 2025

Noah Stansfield
March 12th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Data Roundup: February 2025 Features Updates from WORLDSymposium, Tandem Meetings, and More

Data Roundup: February 2025 Features Updates from WORLDSymposium, Tandem Meetings, and More

CGTLive Staff
March 6th 2025

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025

Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025

Noah Stansfield
March 5th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 26, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 26, 2025

Noah Stansfield
February 26th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 19, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 19, 2025

Noah Stansfield
February 19th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – February 12, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 12, 2025

Noah Stansfield
February 12th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Immix Biopharma’s CAR-T NXC-201 Snags FDA RMAT Designation for Light Chain Amyloidosis

Immix Biopharma’s CAR-T NXC-201 Snags FDA RMAT Designation for Light Chain Amyloidosis

Noah Stansfield
February 10th 2025

The therapy is currently being evaluated for AL amyloidosis in the phase 1b/2 NEXICART-2 clinical trial (NCT06097832) in the United States.

Around the Helix: Cell and Gene Therapy Company Updates – February 5, 2025

Around the Helix: Cell and Gene Therapy Company Updates – February 5, 2025

Noah Stansfield
February 5th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Data Roundup: January 2025 Features Updates for Sarepta's Elevidys in DMD, Tenaya's Hypertrophic Cardiomyopathy Gene Therapy, and More

Data Roundup: January 2025 Features Updates for Sarepta's Elevidys in DMD, Tenaya's Hypertrophic Cardiomyopathy Gene Therapy, and More

CGTLive Staff
February 3rd 2025

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Around the Helix: Cell and Gene Therapy Company Updates – January 29, 2025

Around the Helix: Cell and Gene Therapy Company Updates – January 29, 2025

Noah Stansfield
January 29th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Five Clinical Trial Readouts to Watch in 2025

Five Clinical Trial Readouts to Watch in 2025

CGTLive Staff
January 27th 2025

We've compiled a list of 5 clinical trials with expected data readouts in 2025 that are worth keeping an eye on.

John Leonard, MD, the president and chief executive officer of Intellia

First Patient Dosed in Phase 3 Trial for Intellia Therapeutics’ Hereditary Angioedema Gene Editing Therapy NTLA-2002

Noah Stansfield
January 23rd 2025

The company stated it expects to submit a BLA to the FDA next year.

Around the Helix: Cell and Gene Therapy Company Updates – January 22, 2025

Around the Helix: Cell and Gene Therapy Company Updates – January 22, 2025

Noah Stansfield
January 22nd 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Garners Fast Track Designation

Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Garners Fast Track Designation

Noah Stansfield
January 21st 2025

SGT-212, a dual route gene transfer therapy, is intended to be delivered both by intradentate nucleus infusion and IV infusion at the same time.

Around the Helix: Cell and Gene Therapy Company Updates – January 15, 2025

Around the Helix: Cell and Gene Therapy Company Updates – January 15, 2025

Noah Stansfield
January 15th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Tenaya’s Hypertrophic Cardiomyopathy Gene Therapy TN-201 Well-Tolerated in Early Clinical Data

Tenaya’s Hypertrophic Cardiomyopathy Gene Therapy TN-201 Well-Tolerated in Early Clinical Data

Noah Stansfield
January 9th 2025

The data comes from 3 patients treated at the trial’s low dose.

Around the Helix: Cell and Gene Therapy Company Updates – January 8, 2025

Around the Helix: Cell and Gene Therapy Company Updates – January 8, 2025

Noah Stansfield
January 8th 2025

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

CGTLive's 2024 Pillars of Progress: Top News in Cardiology

CGTLive's 2024 Pillars of Progress: Top News in Cardiology

CGTLive Staff
December 30th 2024

Take a look what stood out as pillars of progress and success from all of CGTLive's most popular cardiology stories in 2024.

Around the Helix: Cell and Gene Therapy Company Updates – December 18, 2024

Around the Helix: Cell and Gene Therapy Company Updates – December 18, 2024

Noah Stansfield
December 18th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – December 11, 2024

Around the Helix: Cell and Gene Therapy Company Updates – December 11, 2024

Noah Stansfield
December 11th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Around the Helix: Cell and Gene Therapy Company Updates – December 4, 2024

Around the Helix: Cell and Gene Therapy Company Updates – December 4, 2024

Noah Stansfield
December 4th 2024

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

1234567>
© 2025 MJH Life Sciences

All rights reserved.